The company’s IntraVascular MRI catheter is intended for the characterization of lipid-rich lesions in the coronary arteries.
Topspin Medical Inc. (TASE:TOPMD) has begun its first clinical trial of its IntraVascular MRI catheter in the US, as part of trials for US Food and Drug Administration (FDA) marketing approval of its product. The trial will be conducted at the Hospital of the University of Pennsylvania. Other medical centers will participate in the trial later. The catheter is intended for the characterization of lipid-rich lesions in the coronary arteries.
Until now, Topspin has carried out clinical trials of its IntraVascular MRI catheter in Israel and Europe, which were not part of the procedures for FDA approval.
Topspin reached agreements with other leading US medical centers, which it intends will participate in the clinical trial in the coming months. The company believes that it will obtain CE Mark certification for marketing its catheter in Europe by the end of this year, and obtain FDA marketing approval by June 2007.
Published by Globes [online], Israel business news - www.globes.co.il - on September 11, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006